Consensus Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Delayed Nasdaq Other stock markets 01:43:40 2024-05-08 pm EDT			5-day change	1st Jan Change
2.79 ^USD	-7.00%		+1.09%	-69.87%

Apr. 19	Bio-Path Closes $1.2 Million Share Offering	MT
Apr. 18	Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	CI

Evolution of the average Target Price on Bio-Path Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6f89b49cc511f88e.rzqiTfRDoV73Ni37i2EXaAuZGwDM5V7xn4DUD23TRz8.62KUCIUc6TO4WXu04zVvAzLGQUSplxGu2OyOQBq-N3bLS_YIkib-MJwEbA~a8059243f3a899f540dbb45e721f04d5

Analyst Recommendations on Bio-Path Holdings, Inc.

HC Wainwright Adjusts Price Target on Bio-Path Holdings to $9 From $12, Reiterates Buy Rating	22-05-19	MT
BIO PATH : HC Wainwright Adjusts Price Target on Bio-Path Holdings to $12 From $10, Maintains Buy Rating	21-04-06	MT
BIO PATH : Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target	21-03-11	MT
BIO PATH : HC Wainwright Adjusts Bio-Path Holdings' Price Target to $10 from $12, Keeps Buy Rating	20-11-16	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3 USD

Average target price

40 USD

Spread / Average Target

+1,233.33%

High Price Target

40 USD

Spread / Highest target

+1,233.33%

Low Price Target

40 USD

Spread / Lowest Target

+1,233.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bio-Path Holdings, Inc.

HC Wainwright
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar